Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of violations of federal securities laws related to misleading statements and undisclosed costs impacting financial results [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Canopy Growth, with a deadline of June 3, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses from Canopy Growth between May 30, 2024, and February 6, 2025, are encouraged to discuss their legal options with Faruqi & Faruqi [1][3]. Group 2: Financial Performance and Allegations - The complaint alleges that Canopy Growth and its executives made false or misleading statements regarding the company's financial health, particularly concerning the costs associated with the Claybourne product launch and Storz & Bickel vaporizer devices [5]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs related to the Claybourne product launch and increased indirect costs [6]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [6]. Group 3: Market Reaction - Following the announcement of its financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [8].

High Tide to Announce Second Fiscal Quarter 2025 Financial ResultsHigh Tide Inc. (“High Tide” or the “Company”) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that it will release its financial and operational results for the quarter ended April 30, 2025, after financial markets close on Monday, June 16, 2025. High Tide’s second fiscal quarter 2025 financial and operational results will ...

Group 1 - Auxly Cannabis Group Inc. will hold its Annual General Meeting of Shareholders on June 30, 2025, at 10:00 a.m. EST in Toronto [1] - Shareholders wishing to attend in person must pre-register with the Company at least 48 hours in advance, and early registration is encouraged [2] - An audio teleconference will be available for shareholders to listen to the Meeting in real time, but they will not be able to vote or participate via teleconference [4] Group 2 - Auxly Cannabis Group Inc. is a leading Canadian consumer packaged goods company in the cannabis products market, headquartered in Toronto [5] - The Company's mission is to help consumers live happier lives through quality cannabis products that they trust and love [5] - Auxly aims to be a leader in branded cannabis products, focusing on quality, safety, and efficacy [5]

Core Viewpoint - Village Farms International has successfully closed a transaction to privatize the majority of its fresh produce business, positioning itself as a leader in the global cannabis industry with a net cash position and significant greenhouse assets [1][2]. Company Overview - Village Farms is a large-scale, vertically-integrated supplier of high-value, plant-based Consumer Packaged Goods, leveraging decades of experience in Controlled Environment Agriculture [3]. - The company has transitioned from being a leading fresh produce supplier to focusing on high-growth cannabinoid opportunities internationally [3]. Cannabis Operations - In Canada, Pure Sunfarms, a wholly-owned subsidiary, is one of the largest cannabis operations globally, with 2.2 million square feet of greenhouse production and recognized as a low-cost producer [4]. - The company has an additional 2.6 million square feet of greenhouse capacity in Canada for future expansion and holds an 80% stake in Rose LifeScience, a leader in cannabis product commercialization [4]. International Expansion - Village Farms is targeting emerging legal cannabis markets with significant growth potential, exporting medical cannabis to countries such as Germany, the UK, Israel, Australia, and New Zealand [5]. - The company is expanding its export business and investing in international production assets, including a license to grow and distribute recreational cannabis in the Netherlands [5]. U.S. Market Strategy - Village Farms plans to enter the U.S. THC market through various strategies, utilizing its Texas-based greenhouse assets, which include 2.2 million square feet of existing capacity and 950 acres of unoccupied land for future expansion [6]. Renewable Energy Initiative - Village Farms Clean Energy, in partnership with Terreva Renewables, generates renewable natural gas from landfill gas, significantly reducing greenhouse gas emissions in Vancouver [7]. Joint Venture and Future Plans - The company holds a 37.9% equity stake in Vanguard Food LP, which aims to create a premier branded CPG foods company through acquisitions and expansion of its product offerings [8].

Core Viewpoint - Institutional Shareholder Services (ISS) recommends that MediPharm shareholders vote for the company's nominees for the Board of Directors, stating that the dissident, Apollo, has not presented a compelling case for change [2][6]. Group 1: ISS Report Findings - The ISS Report concludes that Apollo's claims lack sufficient evidence, highlighting that since Q2 2022, quarterly revenues have more than doubled, adjusted EBITDA has improved from a $6.3 million loss to a $0.1 million gain, and gross margins have expanded by 50.9 percentage points [4][5]. - The report indicates that MediPharm has shown multiple years of improving financial results, particularly under CEO David Pidduck's leadership, and has a logical strategy focusing on higher margin international markets [4][5]. - The ISS Report states that the company has generally outperformed its peers and experienced a clear operational turnaround, contradicting the dissident's claims of peril [4][5]. Group 2: Recommendations for Shareholders - ISS recommends that shareholders vote for the resolution to fix the number of directors at seven, approve MNP LLP as auditors, and authorize the Board to fix their remuneration [6]. - Shareholders are advised to vote against the resolution to approve all unallocated awards under the Company's equity incentive plan [6]. - MediPharm urges shareholders to use the GREEN proxy or voting instruction form to support all of the Company's nominees and resolutions [7][8]. Group 3: Company Background - MediPharm Labs specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and has a GMP-certified facility [9]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale domestic GMP License for cannabinoid extraction [10]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada and internationally [11].

Core Insights - High Tide Inc. will release its financial and operational results for the quarter ended April 30, 2025, on June 16, 2025, after market close [1] - A webcast will be held on June 17, 2025, at 11:30 AM Eastern Time to discuss the results and future outlook [2] Company Overview - High Tide is a leading retail-forward cannabis enterprise and the second-largest cannabis retailer globally by store count, with 200 locations across Canada [4][10] - The company operates various components of the cannabis industry, including retail, e-commerce, and wholesale distribution [4][5][6] Retail Operations - Canna Cabana™ is the largest cannabis retail chain in Canada and was the first cannabis discount club retailer globally [4] - High Tide employs Fastendr™, an automated technology for a better retail experience [5] Product and Brand Portfolio - High Tide has a diverse brand roster, including Queen of Bud™, Cabana Cannabis Co™, and Daily High Club™ [6] - The company is also involved in the CBD market through various platforms [6] Recognition and Growth - High Tide has been recognized as one of Canada's Top Growing Companies for four consecutive years and ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023 [8]

Core Viewpoint - A class action lawsuit has been filed against Canopy Growth Corporation for alleged violations of federal securities laws, specifically regarding misleading statements about production costs and financial performance [1]. Group 1: Lawsuit Details - The lawsuit pertains to shareholders who purchased Canopy's securities between May 30, 2024, and February 6, 2025 [1]. - The complaint claims that Canopy Growth made false statements about significant production costs associated with the launch of Claybourne pre-rolled joints and vaporizer devices, which negatively impacted gross margin and overall financial performance [1]. - The company is accused of overstating the effectiveness of its cost reduction measures, leading to materially misleading public statements throughout the class period [1]. Group 2: Investor Participation - Shareholders who suffered losses during the specified class period are encouraged to contact the DJS Law Group to participate in the lawsuit [2]. Group 3: DJS Law Group Profile - DJS Law Group specializes in enhancing investor returns through securities class actions, corporate governance litigation, and M&A appraisals, representing large hedge funds and alternative asset managers [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of misleading statements and undisclosed costs that negatively impacted the company's financial performance [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Canopy Growth and its executives violated federal securities laws by making false statements and failing to disclose significant costs related to the Claybourne product launch and Storz & Bickel vaporizer devices [4]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs associated with the Claybourne infused pre-roll launch and increased indirect costs related to vaporizer devices [5]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [5]. Group 2: Market Reaction - Following the announcement of the financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [7]. Group 3: Legal Proceedings - Investors who purchased Canopy securities between May 30, 2024, and February 6, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and the June 3, 2025, deadline to seek lead plaintiff status in the class action [2][8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Canopy Growth Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Canopy Growth securities between May 30, 2024, and February 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Canopy Growth made false and misleading statements regarding the costs associated with the launch of its Claybourne pre-rolled joints and the impact on its gross margins [5]. - It is claimed that the defendants overstated the efficacy of Canopy Growth's cost reduction measures while downplaying issues related to its financial health [5].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has bureaus and studios in key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - Automation and software tools, including generative AI, are occasionally used, but all content is edited and authored by humans [5]